Because testing everyone for high levels of blood cholesterol is expensive, a blood test at age 50 may be the most cost-effective method of 4 methods tested to identify those most likely to have a heart attack or stroke in the future. This study result was published recently in the British Medical Journal.
In a purely hypothetical study, the researchers screened 6307 people aged 30 to 74 with no history of heart attack, stroke, or angina. They used 4 different criteria, to see which of the criteria worked best. The researchers also applied the criteria of the Framingham 10-year coronary heart disease risk equation.
First, using the guidelines of the British National Health Services, the researchers selected 43.4% needing the cholesterol test; then they identified 81.2% of those as meeting the Framingham criteria for a 15% greater likelihood of a coronary episode in 10 years.
A second screen, using the Sheffield table?a British set of rules?selected 73.1% of the group as needing the test; the researchers then identified better than 99% of those as meeting the Framingham criteria.
Using fixed values of blood cholesterol, the screening required tests for only 17.8% of the group, with 75.9% of them meeting the Framingham criteria.
The ?winning? test used age 50 as the criterion. This screening found that tests were needed for 46.3% of the group, with 92.8% of them identified as high-risk people. Although not as good as the Sheffield criterion, the age-50 screen is less expensive because fewer tests are needed.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs